Get the Stockscreener App
243.82
1.25%
-3.09
Jazz Pharmaceuticals Plc stock is traded at $243.82, with a volume of 636.25K.
It is down -1.25% in the last 24 hours and up +6.18% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$246.91
Open:
$245.65
24h Volume:
636.25K
Relative Volume:
0.68
Market Cap:
$15.32B
Revenue:
$4.44B
Net Income/Loss:
$29.49M
P/E Ratio:
-13,251.09
EPS:
-0.0184
Net Cash Flow:
$1.19B
1W Performance:
+0.14%
1M Performance:
+6.18%
6M Performance:
+51.32%
1Y Performance:
+116.77%
1-Day Range:
$238.42
$247.26
1-Week Range:
$238.42
$250.49
52-Week Range:
$105.00
$250.49
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
243.82 | 15.32B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
symbol__ Stock Quote Price and Forecast - CNN
JAZZ Maintained by Deutsche Bank -- Price Target Raised to $270 - GuruFocus
Jazz Patent Suit Over Xyrem Survives Dismissal In NJ - Law360
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals (JAZZ) Q4 2024 earnings summary - Quartr
JAZZ Maintains Rating by Truist Securities -- Price Target Lowered to $254 - GuruFocus
Sleep Apnea Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
Jazz Pharmaceuticals (JAZZ) director Cozadd sells 6,000 shares via 10b5-1 trade - Stock Titan
Jazz Pharmaceuticals Holds Steady Near Resistance as Volume Patterns Signal CautionQuality Factor - dars.gov.et
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Growth Potential with a Strategic Focus in Biotechnology - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
JAZZJazz Pharmaceuticals plc Options - Finviz
Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes - simplywall.st
Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP Iannone reports RSU tax-withholding share disposition - Stock Titan
Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed - Stock Titan
Jazz Pharmaceuticals (JAZZ) CFO reports 3,343-share tax withholding - Stock Titan
Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs? - FXEmpire
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD - Investing.com
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD By Investing.com - Investing.com Nigeria
Form 144 Jazz Pharmaceuticals Plc For: 1 July By Investing.com - Investing.com Nigeria
Bruce Cozadd files Form 144 to sell shares — Jazz Pharmaceuticals (NASDAQ: JAZZ) - Stock Titan
Enterprise value to revenue forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Price to earnings forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Price to book forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Is Jazz Pharmaceuticals (JAZZ) Using AbCellera Deal to Quietly Redefine Its Oncology Strategy? - simplywall.st
3 Overrated Stocks Walking a Fine Line - Yahoo Finance UK
Price to sales forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks - AOL.com
Jazz Pharmaceuticals (JAZZ) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary - Quartr
Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary - Quartr
Erica Jefferson Joins Jazz Pharmaceuticals as Chief Communications Officer - hrtoday.in
JAZZ Forecast — Price Target — Prediction for 2027 - TradingView
Jazz Pharmaceuticals' lung cancer drug setback in late-stage trials: Here's why the stock impact may be more limited than it looks - MSN
Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN
Jazz Pharmaceuticals Public Limited Company Actuals & Estimates (NASDAQ:JAZZ) - TradingView
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade) (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals (JAZZ) Reframed Zepzelca Growth, Is The Stock Still Below Fair Value? - simplywall.st
Strong Leaders Build Strong Teamsand Strong Teams Change Patients’ LivesJazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals PLC (HAM:J7Z) Stock Price, Trades & News - GuruFocus
Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses Goal - Yahoo Finance
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration - Yahoo Finance UK
Will Zepzelca’s Failed LAGOON Trial in Second-Line SCLC Change Jazz Pharmaceuticals' (JAZZ) Narrative? - simplywall.st
JAZZ’s Zepzelca fails to meet primary goal in lung cancer study - MSN
Investor Outlook: Jazz Pharmaceuticals Plc (JAZZ) And Its 14.40% Potential Upside - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC (JAZZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback - simplywall.st
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - Yahoo Finance
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):